Ozempic in India 2026: Price After Patent Expiry, Generics & Who Can Take It
In March 2026, Novo Nordisk's Indian patent for semaglutide expired. Within days, Indian pharmaceutical companies launched generic versions at a fraction of the branded price. The cheapest generic now starts at approximately ₹1,290 per month — compared to branded Ozempic at ₹8,800–₹11,175 per month. That is a 90% price reduction.
This guide covers exactly what Ozempic is, who it is for, what it costs today across all available brands, and how to think about eligibility.
Key Takeaways:
- Ozempic is the brand name for semaglutide — a once-weekly injection that manages blood sugar and produces significant weight loss
- Ozempic was approved by CDSCO in September 2025 and officially launched in India in December 2025
- Effective April 1, 2026, Novo Nordisk cut Ozempic prices by up to 36% and Wegovy by up to 48%
- Generic semaglutide starts from ₹325 per weekly injection (vial format), with the same active molecule as Ozempic
- It is a Schedule H drug — available only with a doctor's prescription
- Not covered by Indian health insurance
What Is Ozempic and How Does It Work?
Ozempic is the brand name for semaglutide, made by Novo Nordisk. It belongs to a drug class called GLP-1 receptor agonists (Glucagon-Like Peptide-1).
How it works:
- Stimulates insulin release when blood sugar is high (not when it is low, so hypoglycemia risk is low)
- Suppresses glucagon — the hormone that raises blood sugar
- Slows gastric emptying — food moves from stomach to intestine more slowly, reducing post-meal blood sugar spikes
- Reduces appetite — acts on the brain's appetite-regulating centres to reduce hunger and increase feelings of fullness
The result: lower blood sugar levels and, for most patients, meaningful weight loss even when diet is not perfectly controlled.
Ozempic vs Wegovy — What's the Difference?
Both are semaglutide. The active molecule is identical.
| Ozempic | Wegovy | |
|---|---|---|
| Indication in India | Type 2 diabetes management | Obesity / weight management |
| Approved doses in India | 0.25 mg, 0.5 mg, 1.0 mg | 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg |
| Maximum dose | 1.0 mg/week | 2.4 mg/week |
| CDSCO approved | September 2025 | June 2025 |
Practical reality: Many doctors in India prescribe Ozempic for weight loss as an off-label use. Wegovy is the formally approved obesity-indication brand. For a patient with both type 2 diabetes and obesity, Ozempic is the formally indicated choice.
Ozempic & Generic Semaglutide Prices in India — 2026
Branded Options (Post April 1, 2026 Price Cut)
Novo Nordisk India cut Ozempic prices by an average of approximately 23.8% across all doses and Wegovy by 27–48% following the April 1 revision.
| Brand | Dose | Monthly Cost | Maker |
|---|---|---|---|
| Ozempic | 0.25 mg starter | ~₹5,660–₹6,500 | Novo Nordisk |
| Ozempic | 0.5 mg | ~₹7,500–₹8,500 | Novo Nordisk |
| Ozempic | 1.0 mg | ~₹8,800–₹9,500 | Novo Nordisk |
| Wegovy | 0.25 mg starter | ~₹5,660 | Novo Nordisk |
| Wegovy | 1.7 mg maintenance | ~₹12,000–₹14,400 | Novo Nordisk |
| Mounjaro (tirzepatide) | 2.5 mg starter | ~₹13,125 | Eli Lilly |
Generic Semaglutide Options (Post March 2026 Patent Expiry)
The cheapest GLP-1 in India is now generic semaglutide in vial format. Natco's Semanat and Glenmark's GLIPIQ both retail at approximately ₹325 per weekly dose, or roughly ₹1,300 per month.
| Brand | Format | Weekly Cost | Monthly Cost | Maker |
|---|---|---|---|---|
| Semanat | Vial | ₹325 | ~₹1,290 | Natco Pharma |
| GLIPIQ | Vial | ₹325 | ~₹1,290 | Glenmark |
| Sundae | Pen | ₹220/shot | ~₹880 | Eris Lifesciences |
| Semasize | Pen | ₹450 | ~₹1,800 | Alkem |
| Noveltreat | Pen | ~₹400–500 | ~₹1,600–₹2,000 | Sun Pharma |
| Obeda | Pen | ~₹400–500 | ~₹1,600–₹2,000 | Dr. Reddy's |
Vial vs pen: Vial format requires a separate syringe and slightly more dosing care than a pre-filled pen, so first-time patients usually start on a pen even at the higher price. Discuss with your prescribing doctor.
Warning on counterfeits: The explosion of cheap semaglutide has also created a market for counterfeit and substandard products. Only purchase from a licensed pharmacy with a valid prescription. If a price seems too low (under ₹500/month for a full dose), verify the brand's CDSCO approval status before purchasing.
What Is Rybelsus (Oral Semaglutide)?
Rybelsus is approved in India only for type 2 diabetes — not for weight loss. The US FDA approved an oral formulation for weight management in 2025, but CDSCO has not followed, and Rybelsus costs roughly ₹530–₹760 per week (₹2,300–₹3,300 per month).
Rybelsus requires very specific administration conditions: taken on an empty stomach, with no more than 120 mL of water, 30 minutes before eating or drinking anything else. Non-compliance significantly reduces absorption.
GLP-1 Eligibility Checker — Is Semaglutide Right for You?
Semaglutide is not appropriate for everyone. Use this BMI + eligibility guide to understand whether you fall within the clinical criteria most Indian endocrinologists use for prescribing GLP-1 medications.
This is a guide, not a prescription. The final decision on whether semaglutide is appropriate for you involves a full clinical assessment including cardiovascular history, kidney function, thyroid history, and other medications. Consult an endocrinologist or diabetologist.
Who Is Ozempic / Semaglutide Prescribed For in India?
Formally approved indications:
- Ozempic: Type 2 diabetes mellitus — for adults whose blood sugar is inadequately controlled with diet/exercise alone or with other diabetes medications (metformin, sulfonylureas, etc.)
- Wegovy: Chronic weight management in adults with BMI ≥30 (obesity), or BMI ≥27.5 with at least one weight-related comorbidity (using the WHO Asian BMI cutoff)
Common criteria Indian doctors use:
- BMI ≥30, or
- BMI ≥27.5 with type 2 diabetes, hypertension, dyslipidaemia, or PCOS
- HbA1c above target despite current diabetes medications
- Significant cardiovascular risk (semaglutide has proven cardiovascular benefits in the SUSTAIN trials)
Who should NOT take semaglutide:
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome
- Pregnancy or breastfeeding
- Type 1 diabetes (this is not a type 1 medication — risk of DKA)
- Severe kidney disease (CrCl < 15 mL/min) — use caution and close monitoring
- History of pancreatitis — semaglutide can exacerbate
What Results Can You Expect?
For type 2 diabetes: HbA1c reductions of 1.0%–1.8% at therapeutic doses (0.5–1.0 mg/week), making it one of the most effective non-insulin agents available.
For weight loss: The STEP-1 clinical trial showed average weight loss of 14.9% of body weight over 68 weeks with 2.4 mg/week semaglutide (Wegovy dose) plus lifestyle intervention. At the lower Ozempic doses used for diabetes (1.0 mg), typical weight loss is 4–6 kg over 6 months.
Critical caveat: STEP-1 extension data are unambiguous: patients who stopped semaglutide at week 68 regained roughly two-thirds of their lost weight within a year. Semaglutide works while you take it — it is not a one-time intervention.
Common Side Effects in India
Most side effects are gastrointestinal and typically improve after the first 4–8 weeks:
| Side Effect | Frequency | Management |
|---|---|---|
| Nausea | Very common (30–40%) | Usually improves after 4–8 weeks; eat smaller meals |
| Vomiting | Common (15–20%) | Usually self-limiting |
| Diarrhoea | Common (20%) | Usually self-limiting |
| Constipation | Common (10–15%) | Increase water intake |
| Loss of appetite | Expected — part of the mechanism | Not typically a problem |
| Injection site reactions | Uncommon (< 5%) | Rotate injection sites |
Serious but rare:
- Pancreatitis — stop and seek urgent medical attention if severe abdominal pain develops
- Gallbladder disease — rapid weight loss can increase gallstone risk
- Thyroid C-cell concerns — avoid if personal/family history of MTC
Insurance Coverage — Indian Reality
As of May 2026, no IRDAI-regulated health insurance policy in India covers GLP-1 medication for obesity. Indian policies are hospitalisation-first products — outpatient injectables fall outside standard coverage.
Some employer group health policies may reimburse Ozempic when prescribed specifically for type 2 diabetes management — check your policy documents. Obesity indication reimbursement is not available under any current Indian policy.
How to Get a Prescription in India
Semaglutide is a Schedule H drug — you must have a prescription from a registered medical practitioner. In practice, endocrinologists and diabetologists are the most common prescribers. General physicians can also prescribe it but may be less familiar with titration protocols.
Step 1: Consult an endocrinologist or diabetologist. Bring your most recent HbA1c, fasting blood sugar, lipid profile, and kidney function test reports.
Step 2: The doctor will assess your BMI, cardiovascular risk, diabetes control, and contraindications before prescribing.
Step 3: Purchase from a licensed retail or hospital pharmacy. CDSCO has approved semaglutide for prescription by endocrinologists and internal medicine specialists for diabetes and obesity indications.
Step 4: Follow the titration schedule exactly — starting at 0.25 mg/week for 4 weeks minimises GI side effects. Never increase dose faster than prescribed.
People Also Ask
Is Ozempic available without prescription in India?
No. Ozempic and all semaglutide brands in India are Schedule H drugs — they require a valid prescription from a registered doctor. Online pharmacies that dispense without a prescription are operating illegally.
Is Ozempic the same as semaglutide?
Yes. Ozempic is a brand name; semaglutide is the active molecule. Generic semaglutide (Semanat, GLIPIQ, Sundae, Semasize, etc.) contains the same molecule. The generics that entered the Indian market after March 2026 are CDSCO-approved subsequent new drugs that have demonstrated bioequivalence.
Can Ozempic be used for weight loss in India without diabetes?
Ozempic is formally approved only for type 2 diabetes in India. Wegovy (same molecule, higher dose) is formally approved for obesity. A doctor may prescribe Ozempic for weight loss as an off-label use, but Wegovy is the appropriate on-label product for obesity without diabetes.
How quickly does semaglutide work?
Blood sugar improvement begins in the first few weeks. Meaningful weight loss (2–4 kg) typically becomes noticeable by weeks 6–12. Maximum weight loss effects occur over 9–18 months of continued use. Side effects (nausea) are usually worst in weeks 1–4 and improve significantly after the first month.
Conclusion
Semaglutide entered India as an expensive specialty drug and is rapidly becoming accessible. On March 20, 2026, Novo Nordisk's core Indian patent for semaglutide expired. At about ₹325 per weekly injection, a drug that was priced for an expatriate clientele is now within reach of a Kochi school-teacher.
The clinical evidence is strong: for the right patients — type 2 diabetes inadequately controlled by other medications, or obesity with comorbidities — semaglutide is among the most effective medical tools available. The responsibility now is on prescribers and patients to use it with the right clinical oversight.
If you are considering semaglutide, store your BMI trend, blood sugar reports, and any previous weight-loss attempts in Ayu. When you walk into your endocrinologist's appointment, a documented record of what you have already tried is the strongest case for a GLP-1 prescription.
Medical Disclaimer
This article is for informational and educational purposes only. It does not constitute medical advice or a prescription recommendation. Semaglutide is a prescription-only drug in India (Schedule H). All decisions regarding its use should be made in consultation with a qualified healthcare professional. The BMI eligibility tool provides general guidance and does not substitute for a clinical assessment.
